At a glance
ClinicalIndex Comparison RecordN/ACompleted· 473 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Humira® 40mg Syringe 0.8mL Subcutaneous Injection Special Investigation in Patients With Intestinal Behcet's Disease
In Brief
An observational study for Behcet's Disease. Completed, enrolled 473 participants.
Detailed Summary
This investigation was conducted to obtain the following information regarding the use of Adalimumab (Humira®) 40mg Syringe 0.8mL for Subcutaneous Injection in patients with Intestinal Behcet's Disease. 1. Incidence and conditions of occurrence of adverse reactions in clinical practice 2. Factors likely to affect the safety and effectiveness
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsBehcet's Disease
Countries--
Collaborators--
Timeline
N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartMay 2013
First PostedOct 2013
Primary CompletionMay 2017
TodayJul 2026
First PostedOct 11, 2013
Enrollment StartMay 25, 2013
Primary CompletionMay 15, 2017
TodayJul 2, 2026
Enrollment to primary: 4.0 yearsPosted 12.7 years ago